In a research note sent to investors today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Ligand Pharmaceuticals (NASDAQ:LGND) with a price …
Ligand Pharma (NASDAQ:LGND) partner GlaxoSmithKline (NYSE:GSK) announced it received FDA approval for the sNDA of Promacta for treatment of cytopenia in patients with …